Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1/2 2Phase 2 1Phase 1 1

Status

Unknown 2Recruiting 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 6

Sponsor

Conditions

Breast Neoplasms 9481Neoplasms 6589Prostatic Neoplasms 4399Colorectal Neoplasms 3978Lung Neoplasms 3644Carcinoma, Non-Small-Cell Lung 3585Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Leukemia, Myeloid, Acute 2265Multiple Myeloma 2121Stomach Neoplasms 2109Neoplasm Metastasis 1911Head and Neck Neoplasms 1870Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1730Brain Neoplasms 1702Rectal Neoplasms 1676Melanoma 1656Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1486Esophageal Neoplasms 1312Glioblastoma 1308Lymphoma, Non-Hodgkin 1205Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

Bevacizumab 2regramostim 1recombinant human tumor necrosis factor-binding protein-1 1pembrolizumab 1molgramostim 1irinotecan sucrosofate 1Nivolumab 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Malignant Ascites × Clear all
NCT07490626 2026-03-27

Paracentesis

University of Utah

Phase NA Not yet recruiting
20 enrolled

Malignant Ascites

NCT07397819 2026-02-09

Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy

Sun Yat-sen University

Phase 1/2 Recruiting
48 enrolled

Malignant Ascites

NCT06433869 2024-05-30

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

Sun Yat-sen University

Phase 2 Recruiting
60 enrolled

Malignant Ascites

NCT06200376 2024-01-11

A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer

West China Hospital

Phase 1 Unknown
10 enrolled

Malignant Ascites

NCT05745233 2023-08-24

Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

China Medical University Hospital

Phase NA Enrolling by invitation
30 enrolled

Malignant Ascites

NCT05501340 2022-08-15

PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

Second Affiliated Hospital of Soochow University

Phase 1/2 Unknown
40 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡